0000899243-22-018011.txt : 20220513
0000899243-22-018011.hdr.sgml : 20220513
20220513162853
ACCESSION NUMBER: 0000899243-22-018011
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220510
FILED AS OF DATE: 20220513
DATE AS OF CHANGE: 20220513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Greenberg Bruce
CENTRAL INDEX KEY: 0001928391
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 22923212
MAIL ADDRESS:
STREET 1: C/O ALDEYRA THERAPEUTICS, INC.
STREET 2: 131 HARTWELL AVENUE, SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-05-10
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001928391
Greenberg Bruce
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE, SUITE 320
LEXINGTON
MA
02421
0
1
0
0
See Remarks
Common Stock
7813
D
Employee Stock Option (Right to Buy)
5.32
2029-12-11
Common Stock
45000
D
Employee Stock Option (Right to Buy)
3.57
2030-03-04
Common Stock
20000
D
Employee Stock Option (Right to Buy)
12.24
2031-03-21
Common Stock
58477
D
Employee Stock Option (Right to Buy)
11.28
2031-04-17
Common Stock
29239
D
Employee Stock Option (Right to Buy)
3.50
2032-03-03
Common Stock
100000
D
Employee Stock Option (Right to Buy)
4.52
2032-03-30
Common Stock
73156
D
The shares subject to this option shall vest over 4 years of service following December 12, 2019 with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.
Interim Chief Financial Officer
/s/ Bruce Greenberg
2022-05-13